Cytosorbents CorporationCTSONASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank77
5Y CAGR-12.5%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-12.5%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 20.83% |
| Q2 2025 | 7.00% |
| Q1 2025 | 3.91% |
| Q4 2024 | 7.98% |
| Q3 2024 | -23.14% |
| Q2 2024 | 23.33% |
| Q1 2024 | 51.70% |
| Q4 2023 | -31.17% |
| Q3 2023 | -12.06% |
| Q2 2023 | 16.88% |
| Q1 2023 | -24.15% |
| Q4 2022 | 29.51% |
| Q3 2022 | -7.90% |
| Q2 2022 | -7.26% |
| Q1 2022 | 18.52% |
| Q4 2021 | -76.87% |
| Q3 2021 | -9.77% |
| Q2 2021 | -72.66% |
| Q1 2021 | -8.27% |
| Q4 2020 | -34.43% |
| Q3 2020 | 40.57% |
| Q2 2020 | -33.02% |
| Q1 2020 | 54.35% |
| Q4 2019 | 3.50% |
| Q3 2019 | -55.04% |
| Q2 2019 | 15.29% |
| Q1 2019 | 23.28% |
| Q4 2018 | -106.01% |
| Q3 2018 | 35.27% |
| Q2 2018 | -35.05% |
| Q1 2018 | 18.50% |
| Q4 2017 | -77.06% |
| Q3 2017 | 7.81% |
| Q2 2017 | -49.71% |
| Q1 2017 | 65.93% |
| Q4 2016 | -113.15% |
| Q3 2016 | 20.21% |
| Q2 2016 | -28.56% |
| Q1 2016 | 21.52% |
| Q4 2015 | -23.86% |